<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01795677</url>
  </required_header>
  <id_info>
    <org_study_id>JAK ALLO STUDY</org_study_id>
    <nct_id>NCT01795677</nct_id>
  </id_info>
  <brief_title>JAK2 Inhibitors RUXOLITINIB in Patients With Myelofibrosis</brief_title>
  <official_title>JAK2 Inhibitors RUXOLITINIB in Patients With High or Intermediate Risk Primary or Secondary Myelofibrosis Eligible for Allogeneic Stem Cell Transplantation: a Prospective Multicentric Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French Innovative Leukemia Organisation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>French Innovative Leukemia Organisation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      JAK2 inhibitor RUXOLITINIB before allogeneic hematopoietic stem cell transplantation (HSCT)&#xD;
      in patients with primary or secondary myelofibrosis : a prospective phase II&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      JAK2 inhibitor RUXOLITINIB before allogeneic hematopoietic stem cell transplantation (HSCT)&#xD;
      in patients with primary or secondary myelofibrosis&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Actual">May 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DFS</measure>
    <time_frame>24 months after inclusion</time_frame>
    <description>DFS is defined as the probability to be alive and in remission</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HSCT</measure>
    <time_frame>24 months after inclusion</time_frame>
    <description>Rate of pre-graft splenectomy&#xD;
Co-morbidity score defined by Sorror et al before RUXOLITINIB and after 4-month treatment just before transplantation&#xD;
Post-graft haematological recovery: time to neutrophil engraftment, platelet and red blood cells transfusion independency&#xD;
Acute GVHD grade II-IV incidence&#xD;
Chronic GVHD incidence&#xD;
Overall survival, disease-free survival, non-relapse mortality&#xD;
JAK2V617E allele burden and status at registration, 3, 7, 16 months after inclusion (centralization)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PATIENTS CARACTERISTICS</measure>
    <time_frame>24 months after inclusion</time_frame>
    <description>Patients with and without donor&#xD;
Rate of patients with donor who benefit from a transplantation:&#xD;
Comorbidity score at registration and after 3 months&#xD;
Platelet and red blood cells transfusion independency&#xD;
Performance status evolution (ECOG)&#xD;
General symptoms related to myelofibrosis (questionnaire MF SAF)&#xD;
Comparison of haematological response in patients with or without donor&#xD;
Spleen size evolution&#xD;
Comparison of quality of life in patients with and without (questionnaire EORTC)&#xD;
Comparison of overall survival in patients with and without donor&#xD;
Incidence of severe infections&#xD;
Cytokine measure at registration, 3, and 7 months after inclusion (centralization)&#xD;
MPL JAK status (at registration, centralization</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Myelofibrosis</condition>
  <arm_group>
    <arm_group_label>RUXOLOTINIB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ruxolotinib : patient with donor HSCT 4 months later patients without donor: ruxolotinib alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ruxolotinib</intervention_name>
    <description>Ruxolotinib doses calculated with platelets count and P450 cytochrome inhibitor HSCT for patients with donor</description>
    <arm_group_label>RUXOLOTINIB</arm_group_label>
    <other_name>Kakavi</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 18 and 69 years&#xD;
&#xD;
          -  No comorbidity contraindicating the transplantation :&#xD;
&#xD;
               -  Severe respiratory failure defined as dyspnea grade III or more&#xD;
&#xD;
               -  Severe cardiac failure defined as EF &lt; or = 30%&#xD;
&#xD;
               -  Severe renal failure defined as creatinine clearance &lt; 30 ml/min or dialysis&#xD;
&#xD;
               -  Dementia or non-ability to give informed consent for the protocol&#xD;
&#xD;
               -  Major alteration of performance status defined as ECOG &gt; 2&#xD;
&#xD;
               -  Severe liver disease defined as a cirrhosis or bilirubin &gt; 2 x ULN, or AST/ALT &gt;&#xD;
                  5 x ULN&#xD;
&#xD;
          -  Primary or secondary myelofibrosis diagnosed according to WHO definition (Tefferi, et&#xD;
             al 2007)&#xD;
&#xD;
          -  Palpable splenomegaly or splenomegaly measured by any imagery (maximum size&gt; 15 cm by&#xD;
             ultrasound scan, Magnetic Resonance Imaging or computer tomography)&#xD;
&#xD;
          -  Disease if intermediate or high risk according to published criteria and summarized as&#xD;
             follows:&#xD;
&#xD;
        At least one criterion among the following:&#xD;
&#xD;
          -  Haemoglobin &lt; 100 gr/L (unrelated to medication toxicity)&#xD;
&#xD;
          -  Leucocytes &lt; 4 G/L (unrelated to medication toxicity) or &gt; 25 G/L&#xD;
&#xD;
          -  Poor prognosis cytogenetics : complex karyotype, abnormalities of chromosomes 5, 7 or&#xD;
             17 , +8, 12p-, inv(3), 11q23&#xD;
&#xD;
        Two criteria among the following criteria :&#xD;
&#xD;
          -  General symptoms (weight lost &gt; 10% in less than 6 months, night swears, specific&#xD;
             fever &gt; 37.5Â°C)&#xD;
&#xD;
          -  Peripheral blastosis &gt; 1% observed at least twice&#xD;
&#xD;
          -  Thrombocytopenia &lt; 100 G/L (unrelated to treatment toxicity)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Myelofibrosis transformed into acute leukaemia with 20% blasts of more in blood or&#xD;
             bone marrow&#xD;
&#xD;
          -  Previous treatment with JAK2 inhibitor&#xD;
&#xD;
          -  Thrombopenia &lt; 50 G/L&#xD;
&#xD;
          -  Comorbidities contraindicating the transplantation&#xD;
&#xD;
          -  Comorbidity score Sorror &gt; 3&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MARIE ROBIN, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>FIM/GOELAMS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ROBIN</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.filo-leucemie.org</url>
    <description>FILO internet site</description>
  </link>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>December 21, 2012</study_first_submitted>
  <study_first_submitted_qc>February 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2013</study_first_posted>
  <last_update_submitted>July 17, 2018</last_update_submitted>
  <last_update_submitted_qc>July 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>JAK2 inhibitor RUXOLITINIB</keyword>
  <keyword>Primary or secondary myelofibrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Primary Myelofibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

